Related Experiment Videos

Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells

Kohji Takara1, Masayuki Tsujimoto, Noriaki Ohnishi

  • 1Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan. takara@mb.kyoto-phu.ac.jp

Insights

Digoxin reduces sensitivity to anticancer drugs by increasing MDR1 (P-glycoprotein) expression in Caco-2 cells. This suggests digoxin up-regulates MDR1, impacting drug transport and resistance.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Biochemistry

Background:

  • Multidrug resistance protein 1 (MDR1), also known as P-glycoprotein, is crucial for xenobiotic pharmacokinetics and multidrug resistance.
  • Understanding factors that regulate MDR1 function and expression is vital for drug development and treatment efficacy.

Purpose of the Study:

  • To investigate the effects of digoxin on cancer cell sensitivity to paclitaxel.
  • To assess digoxin's impact on MDR1 function, specifically Rhodamine123 transport.
  • To determine if digoxin influences MDR1 gene (mRNA) expression in human colon carcinoma Caco-2 cells.

Main Methods:

  • Caco-2 cells were pretreated with varying concentrations of digoxin.
  • Cell sensitivity to paclitaxel was measured by growth inhibition assays.
  • MDR1 substrate Rhodamine123 accumulation and efflux were analyzed.
  • MDR1 mRNA levels were quantified using molecular biology techniques.

Main Results:

  • Digoxin pretreatment decreased Caco-2 cell sensitivity to paclitaxel.
  • Digoxin reduced Rhodamine123 accumulation within cells and enhanced its efflux.
  • MDR1 mRNA levels in Caco-2 cells increased in a digoxin concentration-dependent manner.

Conclusions:

  • Digoxin up-regulates MDR1 expression in Caco-2 cells.
  • This up-regulation of MDR1 by digoxin affects drug transport and sensitivity.
  • The findings highlight digoxin's role in modulating P-glycoprotein activity.

Related Concept Videos